HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia.

Abstract
The aim of this study was to evaluate G-CSF receptor (G-CSFr) expression on myeloid blasts, its prognostic significance and role in growth factor use and the safety and efficacy of G-CSF in the treatment of AML. Expression of G-CSFr, CD11a, CD11b, CD11c, CD13, CD33 and CD34 were analyzed with flow cytometry in 101 patients with AML aged 15-60 years. Results were reported as a percentage of positive cells. G-CSFr expression rate was found to be higher in M2 and M3 but lower in M5, M6 phenotypes, and in secondary leukemia. Patients were randomized for G-CSF use. Of 101 cases 51 received G-CSF. The overall remission rate was 68.7%. G-CSF use did not seem to have any effect on the remission rates. The median time to reach neutrophil counts > or = 1000/microliter in cases receiving G-CSF was 23 days, and 28 days in the control group (p < 0.01). G-CSF significantly reduced the number of febrile days (p < 0.01). Early and late relapses of 8 and 16 were observed during follow-up which was not effected by G-CSF use. In patients who were G-CSFr(+), G-CSF use did not alter overall survival rate. Univariate and multivariate analysis have revealed that not sex, G-CSF use or G-CSFr but age, FAB subtype and performance status at diagnosis were the important factors on both overall and disease free survival. We have demonstrated no beneficial effect of G-CSFr analysis on in vivo G-CSF use.
AuthorsSim Kutlay, Meral Beksac, Klara Dalva, Osman Ilhan, Haluk Koc, Hamdi Akan, Muhit Ozcan
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 44 Issue 5 Pg. 791-5 (May 2003) ISSN: 1042-8194 [Print] United States
PMID12802915 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Receptors, Granulocyte Colony-Stimulating Factor
  • Granulocyte Colony-Stimulating Factor
Topics
  • Acute Disease
  • Adult
  • Aged
  • Blast Crisis (pathology)
  • Disease-Free Survival
  • Female
  • Flow Cytometry (methods)
  • Granulocyte Colony-Stimulating Factor (pharmacology, therapeutic use)
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid (diagnosis, drug therapy, mortality)
  • Male
  • Middle Aged
  • Prognosis
  • Receptors, Granulocyte Colony-Stimulating Factor (analysis)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: